Probiotics have long been associated with gut health, but their impact may go far beyond digestion. Emerging research suggests that these beneficial bacteria release tiny vesicles packed with bioactive molecules. These microscopic messengers could play a crucial role in restoring balance in the gut, particularly in people suffering from ulcerative colitis. Scientists are now exploring how these vesicles might form the basis of a new generation of treatments, offering a safer and more effective alternative to conventional therapies.
The gut’s crucial role in overall health
The gut is more than just a digestive organ. It absorbs nutrients, regulates the immune system, and maintains metabolic balance. A healthy gut is essential for overall well-being, but the effects can be widespread when its delicate environment is disrupted. An imbalance in the gut can trigger chronic inflammation, weaken the immune system, and even contribute to metabolic and neurological disorders.
One condition strongly linked to gut imbalance is ulcerative colitis. This form of inflammatory bowel disease (IBD) affects millions of people worldwide. It causes persistent inflammation and ulcers in the colon, leading to symptoms such as abdominal pain, diarrhoea, and rectal bleeding. While conventional treatments, such as anti-inflammatory drugs and immunosuppressants, can help manage symptoms, they come with side effects, including an increased risk of infections. Many patients also experience a loss of effectiveness over time, creating an urgent need for better solutions.
A new frontier: Probiotics and gut health
Probiotics are beneficial bacteria that support a healthy gut environment. They promote the growth of good microbes, suppress harmful bacteria, and strengthen the gut barrier. Some probiotics can even interact with immune cells to help regulate inflammation.
Among them, Bifidobacterium longum is particularly well known for its anti-inflammatory properties. Research suggests that this species can help reduce inflammation by encouraging the production of beneficial immune factors while blocking harmful ones. It also reinforces the gut lining, preventing toxins and bacteria from leaking into the bloodstream. This makes B. longum a promising candidate for managing inflammatory diseases, including ulcerative colitis.
However, scientists have now discovered something even more fascinating Bifidobacterium longum does not just work as a whole bacterium. It also produces tiny extracellular vesicles (EVs) that appear to be key players in gut health. These nanoscale particles could unlock new ways to treat inflammatory diseases without the challenges that come with live bacterial therapies.
The power of bacterial vesicles
Extracellular vesicles are tiny, naturally occurring particles released by bacteria. They act as messengers, carrying proteins, lipids, and genetic material to other bacteria and host cells. This means they can influence the gut environment without the need for live bacteria. Scientists are now investigating how they can be used in medicine, from vaccines to drug delivery systems.
Recent research has shown that B. longum strain NSP001 produces vesicles that have a powerful effect on gut health. These tiny structures help maintain balance in the gut microbiome and regulate immune responses. Their stability, ease of storage, and ability to deliver targeted therapeutic molecules make them a strong candidate for the next generation of probiotic-based treatments.
How bacterial vesicles restore gut balance
In ulcerative colitis, the gut microbiome and immune system become imbalanced. This leads to an overactive immune response, causing chronic inflammation and damage to the intestinal lining. Bacterial vesicles offer a two-fold approach to addressing this imbalance. First, they promote the growth of beneficial bacteria while reducing the presence of harmful microbes. This shift helps restore harmony within the gut microbiome, reducing inflammation at its source. Second, they directly interact with immune cells, helping to regulate the body’s inflammatory response.
Research suggests that B. longum NSP001 vesicles can cross the gut barrier and influence immune cells known as T cells. They appear to suppress harmful Th17 cells, which contribute to inflammation while encouraging the activity of regulatory T cells that help keep the immune system in check (Figure1). These findings suggest that bacterial vesicles could provide a natural and highly targeted way to manage ulcerative colitis, without the risks associated with traditional immunosuppressive drugs.
Credit. Author
Towards a new generation of probiotic therapies
Bacterial vesicles are now being recognised as a new category of postbiotics. Unlike live probiotic bacteria, postbiotics consist of inanimate microbial products that still provide health benefits. This means they offer several advantages over traditional probiotic supplements. One key benefit is stability. Because bacterial vesicles do not contain living organisms, they are easier to store and transport.
They also eliminate the risks associated with live bacterial therapies, such as unintended colonisation or genetic transfer. The potential of bacterial vesicles extends beyond ulcerative colitis. Their ability to regulate immune responses and strengthen gut barrier function makes them promising candidates for treating other conditions, including metabolic disorders and even neurological diseases. As researchers continue to explore these microscopic messengers, they could reshape the future of microbiome-based medicine.
The challenges ahead
Despite their promise, bacterial vesicles are not yet ready for widespread clinical use. Several challenges need to be addressed before they can become a mainstream treatment option. One major hurdle is large-scale production. Scientists must develop reliable methods for producing and purifying bacterial vesicles to maintain their consistency and effectiveness.
Another key challenge is safety. While early studies suggest that vesicles are well tolerated, researchers must conduct thorough testing to rule out any potential adverse effects. Regulatory guidelines also need to be established to ensure quality control and standardisation. Additionally, more work is needed to understand exactly how bacterial vesicles interact with human cells. By refining their therapeutic potential and optimizing delivery methods, researchers can maximise their benefits while minimising unwanted side effects.
A step towards the future of medicine
The discovery of bacterial vesicles represents a turning point in probiotic research. These tiny messengers could pave the way for safer, more effective treatments for ulcerative colitis and other inflammatory diseases. As scientists uncover more about their potential, a crucial question remains: Could harnessing these microscopic particles be the key to revolutionising how we treat chronic gut disorders? The answer may lie in the years ahead, but one thing is clear: bacterial vesicles are opening exciting new possibilities for the future of gut health and beyond.
🔬🧫🧪🔍🤓👩🔬🦠🔭📚
Journal reference
Nie, X., Li, Q., Ji, H., Zhang, S., Wang, Y., Xie, J., & Nie, S. (2025). Bifidobacterium longum NSP001-derived extracellular vesicles ameliorate ulcerative colitis by modulating T cell responses in gut microbiota-(in) dependent manners. npj Biofilms and Microbiomes, 11(1), 27. https://doi.org/10.1038/s41522-025-00663-4
